Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242203 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00242203 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 120 participants.
The verdict
NCT00242203, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Docetaxel
- DRUG Epirubicin
- RADIATION External beam radiation
- DRUG Zometa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2002-10 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242203
The ClinicalTrials.gov registry entry for NCT00242203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT00242203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242203 about?
NCT00242203 is a clinical study titled "Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer". This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.
What is the current status of trial NCT00242203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2002-10. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00242203?
The interventions under investigation include: Trastuzumab (DRUG), Docetaxel (DRUG), Epirubicin (DRUG), External beam radiation (RADIATION), Zometa (DRUG).
Who is sponsoring clinical trial NCT00242203?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.